Immunotherapy for Infectious Diseases: Past, Present, and Future

Manohar, Akshay; Ahuja, Jasmine; Crane, John K.

doi:10.3109/08820139.2015.1093914

Cited by 28 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, anti-CHIKV neutralizing antibody titers may be a protective immune correlate [14][15][16]. Passive immunotherapy has been an important short-term intervention against several infectious diseases, including monoclonal antibody (mAb) prophylaxis against respiratory syncytial virus [17]. However, passive antibody delivery has limitations because of the short half-life of immunoglobulins [18][19][20][21].…”

mentioning

confidence: 99%

Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus

et al. 2016

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus

et al. 2016

View full text Add to dashboard Cite

show abstract

“…This ability of the Salmonella ‐vectored vaccine to produce a protective response against HCV antigens was further confirmed using recombinant L. monocytogenes in a heterologous challenge study. Therapeutic efficacy of bacterial vectors has been described with numerous infectious disease and tumour antigen . Oral immunization of mice with the attenuated Salmonella strain SL7207 expressing HCV core and E2 protein was shown to efficiently induce HCV core and E2‐specific antibodies and cellular immunity …”

Section: Discussionmentioning

confidence: 99%

Development of a recombinant murine tumour model using hepatoma cells expressing hepatitis C virus nonstructural antigens

Young

Haq

MacLean

et al. 2018

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Hepatitis C virus (HCV) chronically infects 2%-3% of the world's population, causing liver disease and cancer with prolonged infection. The narrow host range of the virus, being restricted largely to human hepatocytes, has made the development of relevant models to evaluate the efficacy of vaccines a challenge. We have developed a novel approach to accomplish this by generating a murine hepatoma cell line stably expressing nonstructural HCV antigens which can be used in vitro or in vivo to test HCV vaccine efficacies. These HCV-recombinant hepatoma cells formed large solid-mass tumours when implanted into syngeneic mice, allowing us to test candidate HCV vaccines to demonstrate the development of an HCV-specific immune response that limited tumour growth. Using this model, we tested the therapeutic potential of recombinant anti-HCV-specific vaccines based on two fundamentally different attenuated pathogen vaccine systems-attenuated Salmonella and recombinant adenoviral vector based vaccine. While attenuated Salmonella that secreted HCV antigens limited growth of the HCV-recombinant tumours when used in a therapeutic vaccination trial, replication-competent but noninfectious adenovirus expressing nonstructural HCV antigens showed overall greater survival and reduced weight loss compared to non-replicating nondisseminating adenovirus. Our results demonstrate a model with anti-tumour responses to HCV nonstructural (NS) protein antigens and suggest that recombinant vaccine vectors should be explored as a therapeutic strategy for controlling HCV and HCV-associated cancers.

show abstract

“…Passive immunization is used when there is a high risk of infection and insufficient time for the body to develop its own immune response to a novel pathogen, or to alleviate the symptoms of ongoing infections in patients (Savoy 2020). Since then, significant progress has been made in the field of immunotherapy, from murine monoclonal antibodies to the development of humanized antibodies (Manohar et al 2015).…”

Section: Promising Antibodiesmentioning

confidence: 99%

Smarter cures to combat COVID-19 and future pathogens: a review

Han

Lichtfouse

2021

Environ Chem Lett

View full text Add to dashboard Cite

Prevention is better than cure. A milestone of the anthropocene is the emergence of a series of epidemics and pandemics often characterized by the transmission of a pathogen from animals to human in the past two decades. In particular, the coronavirus disease 2019 (COVID-19) has made a profound impact on emergency responding and policy-making in a public health crisis. Classical solutions for controlling the virus, such as travel restrictions, lockdowns, repurposed drugs and vaccines, are socially unpopular and medically limited by the fast mutation and adaptation of the virus. This is exacerbated by microbial resistance to therapeutic drugs and the slowness of vaccine development. In other words, microbial pathogens are somehow 'smarter' and faster than us, thus calling for more intelligent cures to combat future pandemics. Here, we compare therapeutics for COVID-19 such as synthetic drugs, vaccines, antibodies and phages. We present the strength and limitations of antibiotic and antiviral drugs, vaccines, and antibody-based therapeutics. We describe smarter, cheaper and preventive cures such as bacteriophages, food medicine using probiotics and prebiotics, sports, healthy diet, music, yoga, Tai Chi, dance, reading, knitting, cooking and outdoor activities. Some of these preventive cures have been intuitively developed since thousands of years ago, as illustrated by the fascinating similarity of the Chinese characters for 'music' and 'herbal medicine.'

show abstract

Immunotherapy for Infectious Diseases: Past, Present, and Future

Cited by 28 publications

References 22 publications

Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus

Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus

Development of a recombinant murine tumour model using hepatoma cells expressing hepatitis C virus nonstructural antigens

Smarter cures to combat COVID-19 and future pathogens: a review

Contact Info

Product

Resources

About